ANTX · Company research
AN2 Therapeutics, Inc. Common Stock (ANTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Cash pay becomes 389 shares for AN2 Therapeutics (ANTX) director Patricia A. Martin. - Stock Titan | Cash pay becomes 389 shares for AN2 Therapeutics (ANTX) director Patricia A. Martin. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| A director receives 2,283 shares instead of cash at AN2 Therapeutics (ANTX). - Stock Titan | A director receives 2,283 shares instead of cash at AN2 Therapeutics (ANTX). Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Shares replace cash pay as AN2 Therapeutics (ANTX) director receives 2,465 shares. - Stock Titan | Shares replace cash pay as AN2 Therapeutics (ANTX) director receives 2,465 shares. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics (ANTX) Falls 9.63% to $5.07, Testing Key Support - Retail Volume - https://www.siam.in/ | AN2 Therapeutics (ANTX) Falls 9.63% to $5.07, Testing Key Support - Retail Volume https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 6, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics (ANTX) Falls 9.63% to $5.07, Testing Key Support - Call Flow Alert - dars.gov.et | AN2 Therapeutics (ANTX) Falls 9.63% to $5.07, Testing Key Support - Call Flow Alert dars.gov.et | View source ↗ | dars.gov.et | Oct 6, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics (ANTX) Shares Rise 4.52% to $5.32 as Buyers Test the Upper End of the Recent Range - Technical Analysis - siam.in | AN2 Therapeutics (ANTX) Shares Rise 4.52% to $5.32 as Buyers Test the Upper End of the Recent Range - Technical Analysis siam.in | View source ↗ | siam.in | Oct 1, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK - Stock Titan | AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics (ANTX) Stock Analysis Report | Financials & Insights - Benzinga España | AN2 Therapeutics (ANTX) Stock Analysis Report | Financials & Insights Benzinga España | View source ↗ | Benzinga España | Sep 27, 2026 | neutral | 0 | 0.6 |
| A new medical chief gets an option to buy 233,333 shares at $5.36 from AN2 - Stock Titan | A new medical chief gets an option to buy 233,333 shares at $5.36 from AN2 Stock Titan | View source ↗ | Stock Titan | Sep 16, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics (ANTX) Trades Flat at $5.95 as Stock Consolidates Between Support and Resistance - Buy Signal Reports - https://www.dars.gov.et/ | AN2 Therapeutics (ANTX) Trades Flat at $5.95 as Stock Consolidates Between Support and Resistance - Buy Signal Reports https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Sep 3, 2026 | neutral | 0 | 0.6 |
| Insider Purchase: Director at $ANTX Buys 2,098 Shares - Quiver Quantitative | Insider Purchase: Director at $ANTX Buys 2,098 Shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 2, 2026 | neutral | 0 | 0.6 |
| Insider Purchase: Director at $ANTX Buys 2,098 Shares - Quiver Quantitative | Insider Purchase: Director at $ANTX Buys 2,098 Shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 2, 2026 | neutral | 0 | 0.6 |
| Understanding Momentum Shifts in (ANTX) - Stock Traders Daily | Understanding Momentum Shifts in (ANTX) Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 27, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics reports $8.2 million Q2 net loss and Phase 2 updates - Quiver Quantitative | AN2 Therapeutics reports $8.2 million Q2 net loss and Phase 2 updates Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 11, 2026 | neutral | 0 | 0.6 |
| ANTX Forecast — Price Target — Prediction for 2027 - TradingView | ANTX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 28, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics (ANTX) Slides 4.3% as Shares Test Key Support at $4.21 - Up Down Ratio - po-news-eg.net | AN2 Therapeutics (ANTX) Slides 4.3% as Shares Test Key Support at $4.21 - Up Down Ratio po-news-eg.net | View source ↗ | po-news-eg.net | May 28, 2026 | neutral | 0 | 0.6 |
| Anthem (ANTX) Stock Forecast and Price Target 2026 - MarketBeat | Anthem (ANTX) Stock Forecast and Price Target 2026 MarketBeat | View source ↗ | MarketBeat | Apr 9, 2026 | neutral | 0 | 0.6 |
| AN2 Therapeutics, Inc. Common Stock (ANTX) Stock Price: Oct 8 Close $4.68 - Gotrade | AN2 Therapeutics, Inc. Common Stock (ANTX) Stock Price: Oct 8 Close $4.68 Gotrade | View source ↗ | Gotrade | Mar 11, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Aug 17, 2023 | neutral | 0 | 0.6 |
| ANTX: AN2 Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | ANTX: AN2 Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Jan 27, 2017 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.